Certoparin sodium 3,000units/0.3ml solution for injection pre-filled syringes

Thromboembolic events (TE) are serious complications following glioblastoma (GBM) resection. This retrospective study analyzed 695 GBM patients (2017-2022, University Hospital Dresden) to assess the impact of different anticoagulant regimens-certoparin, enoxaparin, and enoxaparin with intermittent pneumatic stockings (IPS)-along with patient comorbidities, on TE incidence. Overall, 28 patients (4%) developed TE. The highest combined incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) occurred in the enoxaparin group (8.6%), followed by certoparin (6.9%) and enoxaparin + IPS (2.6%) (p = .003). Increased PE risk was associated with longer surgery duration (median 249 vs. 190 min; p = .002), greater intraoperative blood loss (300 vs. 150 mL; p = .002), and older age (> 65 years, p = .043). Comorbidities such as diabetes (p = .005) and coronary heart disease (p = .037) were also linked to elevated TE risk. Multivariate analysis identified enoxaparin alone as an independent risk factor (HR 0.312; CI 0.116-0.842; p = .022). Patients with PE or DVT had surgeries that were on average 45 min longer and involved higher blood loss. GBM patients treated with enoxaparin alone have a significantly higher risk for TE compared to treatment with certoparin or the combination of enoxaparin with IPS. Additionally, the duration of surgery, patient age and comorbidities significantly influence the risk of postoperative TE.

Abstract licence: CC BY 4.0

Abstract Purpose This study aims to evaluate the effectiveness of different thromboprophylaxis regimens, certoparin, enoxaparin, and enoxaparin combined with intermittent pneumatic stockings (IPS), in reducing thromboembolic events (TE) after meningioma surgery, and to identify patient- and procedure-specific risk factors associated with TE. Methods A prospective cohort of 877 patients undergoing surgical resection of meningiomas was analyzed. Patients were stratified into three prophylaxis groups: certoparin, enoxaparin, and enoxaparin + IPS. Clinical variables such as age, sex, comorbidities, blood loss, surgery duration, tumor location and volume were assessed. Statistical analyses included chi-square tests and ANOVA. Results The overall incidence of TE was 3.1% (n = 27). TE rates were similar across groups: certoparin (3.5%), enoxaparin (3.5%), and enoxaparin + IPS (2.6%), with no statistically significant differences (p > .05). Chronic heart disease (p = .002) and surgery duration > 200 minutes (p = .004) were identified as independent risk factors for TE. Conclusion All three thromboprophylaxis regimens demonstrated comparable efficacy in preventing postoperative TE. Although not statistically significant, the combination of enoxaparin and IPS was associated with the lowest TE rate and no fatal events. These findings support risk-adapted prophylaxis strategies in patients with elevated procedural or cardiovascular risk.

Abstract licence: CC BY

Abstract Thromboembolic events (TE) are serious complications following glioblastoma (GBM) resection. This retrospective study analyzed 695 GBM patients (2017–2022, University Hospital Dresden) to assess the impact of different anticoagulant regimens—certoparin, enoxaparin, and enoxaparin with intermittent pneumatic stockings (IPS)—along with patient comorbidities, on TE incidence. Overall, 28 patients (4%) developed TE. The highest combined incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) occurred in the enoxaparin group (8.6%), followed by certoparin (6.9%) and enoxaparin + IPS (2.6%) (p = .003). Increased PE risk was associated with longer surgery duration (median 249 vs. 190 min; p = .002), greater intraoperative blood loss (300 vs. 150 mL; p = .002), and older age (>65 years, p = .043). Comorbidities such as diabetes (p = .005) and coronary heart disease (p = .037) were also linked to elevated TE risk. Multivariate analysis identified enoxaparin alone as an independent risk factor (HR 0.312; CI 0.116–0.842; p = .022). Patients with PE or DVT had surgeries that were on average 45 minutes longer and involved higher blood loss. GBM patients treated with enoxaparin alone have a significant higher risk for TE compared to treatment with certoparin or the combination of enoxaparin with IPS. Additionally, the duration of surgery, patient age and comorbidities significantly influence the risk of postoperative TE.

Abstract licence: CC BY